Anthropic Acquires Rare Disease Drug Developer Mithril Medicine
AI company Anthropic has completed the acquisition of Mithril Medicine, a biotechnology firm focused on developing therapies for two rare forms of muscular dystrophy. The acquired entity was uniquely structured with founder Cody Tranbarger serving as its sole employee. The deal highlights an increasing intersection between generative AI and drug discovery. Tranbarger noted that Anthropic's Claude AI model played an instrumental role in his research and development processes, suggesting that advanced large language models are becoming core components in specialized scientific workflows.
Topics: Artificial Intelligence Biotechnology M&A